Plasma chemerin levels in patients with multiple sclerosis.

Area of Science:

• Endocrinology
• Neuroimmunology
• Metabolic Syndrome Research

Background:

• Chemerin, an adipokine from adipose tissue and liver, correlates with metabolic syndrome markers.
• Chemerin acts as a chemoattractant, potentially influencing immune cell functions.

Purpose of the Study:

• To determine plasma chemerin concentrations in multiple sclerosis (MS) patients.
• To investigate the association between chemerin levels, body weight status, and MS.

Main Methods:

• Plasma chemerin levels were measured using ELISA in 39 MS patients (lean and overweight/obese) and 42 controls.
• Included MRI, cerebrospinal fluid analysis for oligoclonal bands and IgG index, and Expanded Disability Status Scale assessment.
• Lipid profile, glucose, insulin, CRP, and cytokine levels were also analyzed.

Main Results:

• Overweight/obese MS patients exhibited significantly higher plasma chemerin concentrations compared to lean MS patients and both lean and overweight/obese controls.
• A significant difference was observed between overweight/obese MS patients and lean controls.

Conclusions:

• Elevated plasma chemerin levels in multiple sclerosis patients are associated with overweight and obesity.
• This suggests a potential link between adiposity, chemerin, and MS pathophysiology.